BioCentury - Alzheimer's play Alzheon files for IPO
BioCentury,
Alzheon Inc. (Framingham, Mass.) filed to raise up to $80.5 million in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray…
Alzheon Inc. (Framingham, Mass.) filed to raise up to $80.5 million in an IPO on NASDAQ underwritten by Citigroup, Piper Jaffray…
14 Dec 2017 They are difficult to isolate, hard to quantify, and virtually uncharacterized structurally.
A Alzheon Presents New Data for Lead Candidate ALZ801 on Novel MOA and LongTerm Clinical Efficacy at the Alzheimer's…
FRAMINGHAM, Mass.--(Business Wire)-- Alzheon, Inc., a clinical stage biopharmaceutical company focused on developing new…
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for…
FRAMINGHAM, Mass.--( BUSINESS WIRE )-- Alzheon, Inc., a clinical stage biopharmaceutical company focused on developing new…
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for…
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for…
FRAMINGHAM, Mass.--(Business Wire)-- Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new…
FRAMINGHAM, Mass.--(Business Wire)--Results published today by Alzheon, Inc., in The Journal of the Prevention of Alzheimer’s…
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for…
FRAMINGHAM, Mass.--( BUSINESS WIRE )--Results published today by Alzheon, Inc., in The Journal of the Prevention of Alzheimer’s…
Analyses from Phase 3 Studies Published in The Journal of the Prevention of Alzheimer’s Disease Show Strongest Clinical Benefit…
FRAMINGHAM, Mass.--( BUSINESS WIRE )-- Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new…
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for…
Presentations Highlight Recent Discovery of Inhibition of Formation of Toxic Beta Amyloid Oligomers and New Insights for…
Analyses from Phase 3 Studies Published in The Journal of the Prevention of Alzheimer’s Disease Show Strongest Clinical Benefit…
Published Data Shows that Novel ‘Enveloping’ Mechanism of Tramiprosate Modulates Misfolding of Aß42 Amyloid and Prevents…
12 May 2017 Despite the litany of failed Alzheimer’s drugs, academic and industry researchers at the 13th International…
Cette étude à l’initiative du fabricant de la molécule, Alzheon Inc., révèle un nouveau mécanisme de blocage de l’amyloïde et…
Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action…
In a paper published in CNS Drugs, researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action for…
In a paper published in CNS Drugs, researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action for…
- Alzheon, Inc. today announced publication of a newly elucidated molecular mechanism of action for tramiprosate, the active…
Alzheon, Inc. today announced publication of a newly elucidated molecular mechanism of action for tramiprosate, the active…
FRAMINGHAM, Mass.--(Business Wire)-- Alzheon, Inc. today announced publication of a newly elucidated molecular mechanism of…
Published Data Shows that Novel ‘Enveloping’ Mechanism of Tramiprosate Modulates Misfolding of Aß42 Amyloid and Prevents…
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc. today announced publication of a newly elucidated molecular mechanism of…
FRAMINGHAM, Mass.--( BUSINESS WIRE )-- Alzheon, Inc. today announced publication of a newly elucidated molecular mechanism of…
FRAMINGHAM, Mass., April 25, 2017 - Alzheon, Inc. today announced publication of a newly elucidated molecular mechanism of…
Published Data Shows that Novel ‘Enveloping’ Mechanism of Tramiprosate Modulates Misfolding of Aß42 Amyloid and Prevents…